CRISPR-Cas9
Also called: CRISPR, Genome editing · Topic: Human Capital: Education, Health and Demographic Dividend · NCERT: Beyond NCERT
Meaning
CRISPR-Cas9 is a gene-editing tool. A short guide RNA leads the Cas9 enzyme (a protein that acts like molecular scissors) to a chosen spot in the DNA, and Cas9 cuts the DNA there. When the cell repairs the cut, a gene can be switched off, corrected or replaced.
It is the main technology behind modern genome editing. For an economist, it is a new tool of curative medicine: it could cure inherited diseases and so protect the health side of human capital. But gene editing is advancing faster than the rules that govern it, and WHO says oversight is needed at both national and transnational levels.
Explanation
How it works
- CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. These are repeated stretches of DNA in bacteria. Bacteria use them, together with Cas proteins, as an immune system that remembers viruses and cuts up their DNA. Scientists turned this natural system into a tool.
- Two parts:
- Guide RNA: a short RNA strand built to match the target DNA sequence. It works like a GPS address.
-
Cas9: an enzyme that cuts both strands of the DNA at the spot the guide RNA marks.
-
What happens after the cut: the cell repairs the break itself, in one of two ways.
- Gene disabled: the repair is quick and sloppy (non-homologous end joining) → small errors appear → the gene stops working.
-
Gene corrected or replaced: scientists supply a correct DNA template → the cell copies it into the gap (homology-directed repair) → a faulty gene is fixed.
-
Why it spread so fast: older tools needed a new protein designed for every target. CRISPR needs only a new guide RNA, so it is cheaper, faster and more precise.
Types of use: somatic vs germline
- Somatic editing changes only the patient's own body cells. The changes are not passed on to children.
- Ex-vivo: cells are taken out, edited outside the body and put back.
-
In-vivo: the editing tool is delivered directly into the patient's body. This carries different risks.
-
Germline (heritable) editing changes embryos, eggs or sperm, so the changes can pass to future generations. WHO says heritable editing is generally considered of greater ethical concern.
- The 2018 He Jiankui affair (gene-edited babies in China) was germline editing. It led WHO to set up its expert committee in December 2018.
What creates risk
- Off-target cuts: Cas9 may cut a similar-looking DNA site by mistake.
- Immune reactions: in a Chinese gene-therapy trial for Duchenne muscular dystrophy, one participant had a catastrophic immune reaction, and the therapy gave only limited benefit.
- Weak oversight: in a Shanghai trial, a six-year-old girl with Snijders Blok-Campeau syndrome (a rare, non-life-threatening neurodevelopmental condition) died in 2025. Her death was left out of a Nature paper published on 18 February 2026.
- Primate (monkey) safety results did not reach the hospital's clinical lead in time.
- The death came to light only through a Science and Retraction Watch investigation in July 2026.
Global governance
- WHO released two linked documents on 12 July 2021:
- Human genome editing: a framework for governance. It can be used at institutional, national, regional or international level and includes 7 illustrative scenarios.
-
Recommendations covering 9 areas, including a global registry of human genome editing research, reporting of illegal or unsafe research, international research and medical travel, and intellectual property (IP).
-
WHO's committee also produced a Director-General policy statement on germline editing.
In India
- No single dedicated law. India regulates gene editing through several rules and guidelines:
- New Drugs and Clinical Trials Rules, 2019: CRISPR therapies come under CDSCO (India's drug and clinical-trial regulator).
- National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, issued by CDSCO, ICMR and DBT.
- RCGM (Review Committee on Genetic Manipulation) and institutional biosafety committees check lab-stage biosafety under the 1989 Rules made under the Environment (Protection) Act.
-
Ethics committees follow ICMR's 2017 national ethical guidelines.
-
DBT's draft genome-editing framework (January 2020) links only ex-vivo editing explicitly to the existing gene and cell therapy guidelines. In-body (in-vivo) editing has no such explicit link.
- The gap: lab biosafety (RCGM) and clinical approval (CDSCO) sit with separate bodies. This is the same hand-off point where the Shanghai trial failed.
- A Parliamentary Standing Committee on Health report recommended specialist scientific review cadres in CDSCO.
- BIRSA-101: CSIR-IGIB's home-grown CRISPR therapy for sickle cell disease, described as India's first, has been licensed to Serum Institute of India. This matters for human capital because sickle cell disease shortens working lives and lowers productivity.
- Health-finance link: out-of-pocket spending was about 39% of total health spending (National Health Accounts 2021-22), and government health spending was about 1.8% of GDP. Costly new therapies will only build human capital widely if public insurance such as PM-JAY (₹5 lakh per family per year) or public funding can cover them.
Don't confuse with
- Somatic vs germline editing: somatic changes stay with the patient. Germline changes pass to children and raise greater ethical concern. The 2026 Shanghai case was somatic gene therapy, not embryo editing.
- Gene therapy: the broad idea of treating disease by changing or adding genes. Many older gene therapies add a working gene without cutting the DNA. CRISPR is one specific tool that cuts and edits DNA at an exact site.
- Genetically modified (transgenic) organisms: these usually carry a gene from another species. CRISPR editing can change an organism's own genes without adding foreign DNA.
- WHO Framework vs WHO Recommendations (2021): the Framework covers values, tools and 7 scenarios. The Recommendations cover 9 areas. They are two separate documents.
Prelims Hooks
- CRISPR-Cas9 has two parts: a guide RNA, which finds the target DNA, and Cas9, the enzyme that cuts it. The system comes from a bacterial immune defence against viruses.
- WHO set up its Expert Advisory Committee on human genome editing in December 2018 and issued its Framework and Recommendations on 12 July 2021. Trap: mixing up the two years.
- One of WHO's nine recommendation areas is a global registry of human genome editing research.
- In India, CRISPR therapies come under CDSCO through the NDCT Rules, 2019. Lab biosafety comes under RCGM through the 1989 Rules of the Environment (Protection) Act. Trap: "RCGM approves clinical trials" is FALSE.
- BIRSA-101 (CSIR-IGIB) is a CRISPR therapy for sickle cell disease, licensed to Serum Institute of India.
- DBT's January 2020 draft framework explicitly links only ex-vivo genome editing to the existing gene therapy guidelines.
Mains Points
- A tool for human capital, with a cost barrier. CRISPR could cure inherited diseases like sickle cell disease, so it is an investment in curative health that gives a longer, uninterrupted labour supply. But:
- out-of-pocket spending is already about 39% of health spending (NHA 2021-22);
- so costly therapies may reach only the rich unless PM-JAY or public funding covers them;
-
otherwise the gap in health, and in human capital, between rich and poor will widen.
-
Regulation is behind the science. India relies on guidelines, separate bodies and a draft framework from 2020. Before BIRSA-101 reaches many patients:
- build specialist review cadres in CDSCO;
- make it compulsory for animal-study results to reach the hospital ethics committee before treatment begins, which is the exact point where the Shanghai trial failed;
-
list Indian trials on WHO's registry.
-
Punishing after harm vs preventing harm. China dismissed the scientists and banned them from projects for 5 years, but only after journalists exposed the case. Prevention needs registration and transparency checks before the first patient is treated, not just penalties afterwards. The same applies to market failure in health: patients and families do not have full information, so the state must set standards (as in Section 7 of the human capital note).